🇨🇭·Nov 18, 2024Industry
Alentis Receives FDA Fast Track Designation for ALE.P02 for the Treatment of CLDN1+ Squamous Solid Tumors
Publisher
A
Alentis Therapeutics
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Alentis Therapeutics
- Region
- Switzerland
- Scope
- Industry
- Published
- November 18, 2024
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on alentis.ch
Leave the platform to read the original full article on the publisher site.
Source: Alentis Therapeutics
Scope: Industry
Related coverage
More related coverage
SELLAS Life Sciences·21h ago
Company - Sellas Life Sciences
Hyman, Phelps & McNamara (FDA Law)·22h ago
WuXi AppTec’s 1260H Listing Brings the BIOSECURE Act Back to Center Stage
Sumitomo Pharma·1d ago
Update on Patient Enrollment in Phase 2 Study of Enzomenib for Acute Leukemia
Menicon·1d ago